Senti Bio appoints Jay Cross as CFO and Faraz Siddiqui as SVP Technical Operations

Senti Biosciences, Inc.

Jay Cross appointed CFO effective March 3, 2025; base salary $465k, annual target bonus 40%, sign-on bonus $50k repayable if leaving before 14 months.
Stock option for 174,200 shares (or 44,000 if stockholder proposal fails) under 2022 Inducement Plan; four-year vesting.
Faraz Siddiqui joined as SVP Technical Operations in Jan 2025; oversees manufacturing, supply chain; previously at IGM Biosciences, Instil Bio, Kite Pharma, Genentech.
CEO Timothy Lu served as interim principal financial officer from Jan 31 until 10-K filing when Cross assumes role.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jay Cross

Chief Financial Officer

SNTI · Senti Biosciences, Inc.

Effective: 2025-03-03
Filed: February 25, 2025, 6:59 PM ET

Jay Cross was appointed as the Company’s Chief Financial Officer, effective as of March 3, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jay Cross was appointed as Chief Financial Officer at Senti Biosciences, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Jay Cross was appointed as the Company’s Chief Financial Officer, effective as of March 3, 2025.

View on SEC.gov

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-25-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.